DMS Imaging (XBRU:ALIMG) FCF Margin % : -7.68% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is DMS Imaging FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. DMS Imaging's Free Cash Flow for the six months ended in Dec. 2023 was €-1.52 Mil. DMS Imaging's Revenue for the six months ended in Dec. 2023 was €19.75 Mil. Therefore, DMS Imaging's FCF Margin % for the quarter that ended in Dec. 2023 was -7.68%.

As of today, DMS Imaging's current FCF Yield % is -13.55%.

The historical rank and industry rank for DMS Imaging's FCF Margin % or its related term are showing as below:

XBRU:ALIMG' s FCF Margin % Range Over the Past 10 Years
Min: -207325 Med: -11.94 Max: -0.33
Current: -11.94

During the past 12 years, the highest FCF Margin % of DMS Imaging was -0.33%. The lowest was -207325.00%. And the median was -11.94%.

XBRU:ALIMG's FCF Margin % is ranked better than
72.42% of 1037 companies
in the Biotechnology industry
Industry Median: -147.18 vs XBRU:ALIMG: -11.94

DMS Imaging FCF Margin % Historical Data

The historical data trend for DMS Imaging's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMS Imaging FCF Margin % Chart

DMS Imaging Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-4.34

-0.33

-11.94

DMS Imaging Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															1.67	-1.76	14.14	-15.98	-7.68

Competitive Comparison of DMS Imaging's FCF Margin %

For the Biotechnology subindustry, DMS Imaging's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DMS Imaging's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DMS Imaging's FCF Margin % distribution charts can be found below:

* The bar in red indicates where DMS Imaging's FCF Margin % falls into.

DMS Imaging FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

DMS Imaging's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-4.843	/	40.564
	=	-11.94 %

DMS Imaging's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.516	/	19.748
	=	-7.68 %

DMS Imaging FCF Margin % Related Terms

Thank you for viewing the detailed overview of DMS Imaging's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

DMS Imaging (XBRU:ALIMG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (XBRU:ALIMG) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AS0:Germany

Address

7 Rue des Chasseurs Ardennais, Liege, BEL, 4031

Website

https://www.dms-imaging.com

DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

DMS Imaging (XBRU:ALIMG) Headlines

No Headlines